An FDA-approved drug structurally and phenotypically corrects the K210del mutation in genetic cardiomyopathy models.
Wang P, Ahmed MS, Nguyen NUN, Menendez-Montes I, Hsu CC, Farag AB, Thet S, Lam NT, Wansapura JP, Crossley E, Ma N, Zhao SR, Zhang T, Morimoto S, Singh R, Elhelaly W, Tassin TC, Cardoso AC, Williams NS, Pointer HL, Elliott DA, McNamara JW, Watt KI, Porrello ER, Sadayappan S, Sadek HA.
Wang P, et al. Among authors: zhang t.
J Clin Invest. 2025 Feb 17;135(4):e174081. doi: 10.1172/JCI174081.
J Clin Invest. 2025.
PMID: 39959972
Free PMC article.